
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant, or other professional adviser.

If you have sold or transferred all your shares in Hua Xia Healthcare Holdings Limited (the “Company”), you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

**HUA XIA HEALTHCARE HOLDINGS LIMITED****華夏醫療集團有限公司****(incorporated in the Cayman Islands with limited liability)***(Stock Code: 8143)**

- (1) PROPOSED GENERAL MANDATES TO ISSUE
AND REPURCHASE SHARES;**
- (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS
AND CONTINUOUS APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTORS
WHO HAVE SERVED FOR MORE THAN NINE YEARS;
AND**
- (3) NOTICE OF ANNUAL GENERAL MEETING**

A notice convening the annual general meeting (the “AGM”) of the Company to be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Friday, 10 August 2018 at 3:30 p.m. is set out on pages 21 to 25 of this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM, you are requested to complete the form of proxy in accordance with the instruction printed thereon and return the same to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM (i.e. no later than 3:30 p.m. on Wednesday, 8 August 2018 (Hong Kong time)) or any adjournment of such meeting. Completion and return of the enclosed form of proxy will not preclude you from attending and voting in person at such meeting or any adjournment meeting should you so wish.

This circular will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and the website of the Company at www.huaxia-healthcare.com.

11 July 2018

* For identification purpose only

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	
INTRODUCTION	3
(1) PROPOSED GENERAL MANDATE TO ISSUE AND REPURCHASE SHARES	4
(2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF PROF. HU SHANLIAN AND PROF. LU CHUANZHEN	6
(3) ANNUAL GENERAL MEETING	7
CLOSURE OF REGISTER OF MEMBERS	7
GEM LISTING RULES REQUIREMENT FOR VOTING	7
SHAREHOLDERS ABSTAIN FROM VOTING	7
RESPONSIBILITY STATEMENT	8
RECOMMENDATIONS	8
GENERAL	8
 APPENDIX I – EXPLANATORY STATEMENT	 9
 APPENDIX II – DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED	 15
 NOTICE OF ANNUAL GENERAL MEETING	 21

DEFINITIONS

In this circular, the following expression shall have the following meanings unless the context otherwise requires:

“acting in concert”	has the same meaning ascribed to it under the Takeovers Code
“AGM”	the annual general meeting of the Company to be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Friday, 10 August 2018 at 3:30 p.m.
“Articles of Association”	articles of association of the Company, as amended from time to time
“Board”	the board of Directors
“close associates”	have the same meaning as prescribed in the GEM Listing Rules
“Company”	Hua Xia Healthcare Holdings Limited, a company incorporated in the Cayman Islands with limited liability, the issued Shares of which are listed on GEM (stock code: 8143)
“Companies Law”	the companies law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands
“Director(s)”	the director(s) of the Company
“GEM”	GEM of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“General Mandate”	the general mandate proposed to be granted to the Directors at the AGM to allot, issue and deal with new Shares not exceeding 20% of the total number of issued Shares as at the date of the AGM which is to be extended by the number of Shares purchased pursuant to the Repurchase Mandate
“Group”	the Company and its subsidiaries

DEFINITIONS

“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	9 July 2018, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“PRC”	the People’s Republic of China, which for the purpose of this circular excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Repurchase Mandate”	a general and unconditional mandate to be granted to the Directors at the AGM to exercise all powers of the Company to repurchase Shares up to a maximum of 10% of the total number of issued Shares as at the date of passing of the relevant resolution granting such mandate
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Shareholder(s)”	holder(s) of the Shares
“Shares”	ordinary shares of HK\$0.01 each in the issued share capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“%”	per cent.

LETTER FROM THE BOARD



HUA XIA HEALTHCARE HOLDINGS LIMITED

華夏醫療集團有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

Executive Directors:

Dr. Jiang Tao (*Chief Executive Officer*)
Mr. Zheng Gang
Dr. Huang Jiaqing
Mr. Yung Ka Chun
Mr. Lin Jinzong

Registered office:

P.O. Box 10008
Willow House
Cricket Square
Grand Cayman KY1-1001
Cayman Islands

Non-executive Directors:

Dr. Wong Yu Man, James
Mr. Tang Xun
Mr. Chan Chi Ming, Tony

*Head office and principal place of
business in Hong Kong:*

19th Floor, New Wing
101 King's Road
Hong Kong

Independent non-executive Directors:

Ms. Wong Ka Wai, Jeanne
Prof. Hu Shanlian
Prof. Lu Chuanzhen
Prof. Zhang Bin
Dr. Lam Huen Sum
Mr. Liu Chenli

11 July 2018

*To Shareholders of the Company, and for information only,
holder(s) of options and convertible preference shares*

Dear Sir or Madam,

**(1) PROPOSED GENERAL MANDATES TO ISSUE
AND REPURCHASE SHARES;
(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS
AND CONTINUOUS APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTORS
WHO HAVE SERVED FOR MORE THAN NINE YEARS;
AND
(3) NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information regarding certain resolutions to be proposed at the forthcoming AGM of the Company to be held on Friday, 10 August 2018 at 3:30 p.m., including but not limited to (i) ordinary resolutions relating to the grant of General Mandate and Repurchase Mandate to the Directors for the issue and repurchase of its Shares; and (ii) ordinary resolution relating to the re-election of the retiring Directors and continuous appointment of Prof. Hu Shanlian and Prof. Lu Chuanzhen as independent non-executive Directors.

* For identification purpose only

LETTER FROM THE BOARD

(1) PROPOSED GENERAL MANDATE TO ISSUE AND REPURCHASE SHARES

The existing general mandate granted to the Directors to allot and issue new Shares and to repurchase Shares at the annual general meeting of the Company held on 14 August 2017 will lapse at the conclusion of the AGM.

At the AGM, ordinary resolutions will be proposed to the Shareholders (a) approving the grant of the General Mandate to the Directors to allot, issue and otherwise deal in the new Shares not exceeding 20% of the total number of issued Shares as at the date of passing such resolution; (b) approving the grant of the Repurchase Mandate to the Directors to repurchase, inter alia, Shares, the number of which does not exceed 10% of the total number of issued Shares as at the date of passing such resolution; and (c) adding to the total number of Shares which may be allotted, issued or dealt in under the General Mandate the number of Shares repurchased by the Company under the Repurchase Mandate.

The General Mandate

Under the General Mandate, the Directors will be given a general mandate to allot, issue and deal in the new Shares representing not more than 20% of the total number of issued Shares as at the date of passing such resolution.

As at the Latest Practicable Date, the Company had an aggregate of 2,818,249,944 Shares in issue. Subject to the passing of the ordinary resolution for the approval of the General Mandate and assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the General Mandate to allot, issue and deal in up to a maximum of 563,649,988 new Shares.

The Repurchase Mandate

It is also proposed that the Repurchase Mandate be granted to the Directors.

Under the Repurchase Mandate, the Directors will be given a repurchase mandate to repurchase Shares representing not more than 10% of the total number of issued Shares as at the date of passing such resolution, on GEM or on any stock exchange recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange.

LETTER FROM THE BOARD

As at the Latest Practicable Date, the Company had an aggregate of 2,818,249,944 Shares in issue. Subject to the passing of the ordinary resolution for the approval of the Repurchase Mandate and assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the Repurchase Mandate to repurchase up to a maximum of 281,824,994 Shares.

The explanatory statement required by the GEM Listing Rules to be sent to the Shareholders in connection with the proposed Repurchase Mandate is set out on pages 9 to 14 of this circular.

The Directors wish to state that they have no present intention to repurchase any Shares.

Extension of the General Mandate

Subject to the approval of the Repurchase Mandate, another ordinary resolution will be proposed at the AGM to add to the limit under the General Mandate the number of Shares repurchased by the Company pursuant to the Repurchase Mandate.

Effectiveness of General Mandate and Repurchase Mandate

The General Mandate and the Repurchase Mandate shall be effective until whichever is the earliest of:

- (a) the conclusion of the next annual general meeting of the Company; or
- (b) the expiration of the period within which the next annual general meeting of the company is required by the Articles of Association, or any applicable law of the Cayman Islands to be held; or
- (c) the passing of an ordinary resolution by the Shareholders in a general meeting revoking or varying the authority given to the Directors.

LETTER FROM THE BOARD

(2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF PROF. HU SHANLIAN AND PROF. LU CHUANZHEN

According to article 86(3) of the Articles of Association, the Board shall have the power from time to time and at any time to appoint any person as Director either to fill a casual vacancy or as an additional Director. Any Director so appointed should be subject to election by Shareholders at the first general meeting after the appointment and shall then be eligible for re-election.

In accordance with article 86(3) of the Articles of Association, Dr. Lam Huen Sum and Mr. Liu Chenli shall retire from their offices at the AGM and, being eligible, will offer themselves for re-election.

According to article 87(1) of the Articles of Association, at each annual general meeting, one-third of the Directors for the time being (or, if their numbers is not a multiple of three, then the number nearest to but not less than one-third) shall retire from office by rotation, provided that every Director (including those appointed for a specific term) shall be subject to at least once in every three years. A retiring Director shall be eligible for re-election.

In accordance with article 87(1) of the Articles of Association, Mr. Tang Xun, Dr. Wong Yu Man, James, Prof. Hu Shanlian and Prof. Lu Chuanzhen shall retire from their offices at the AGM and, being eligible, will offer themselves for re-election.

According to code provision A.4.3 of the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules, if an independent non-executive director serves more than nine years, any further appointment of such independent non-executive director should be subject to a separate resolution to be approved by Shareholders. Each of Prof. Hu Shanlian (“**Prof. Hu**”) and Prof. Lu Chuanzhen (“**Prof. Lu**”) has been appointed as an independent non-executive Director for more than ten years. The Company has received from each of Prof. Hu and Prof. Lu a confirmation of independence according to Rule 5.09 of the GEM Listing Rules. Each of Prof. Hu and Prof. Lu has not engaged in any executive management of the Group. Taking into consideration of their independent scope of work in the past years, the Directors consider each of Prof. Hu and Prof. Lu to be independent under the GEM Listing Rules despite the fact that they have served the Company for more than ten years. The Board believes that Prof. Hu’s and Prof. Lu’s continued tenure bring considerable stability to the Board and the Board has benefited greatly from the presence of Prof. Hu and Prof. Lu who have over time provided valuable insight to the Group.

At the AGM, ordinary resolutions will be proposed to re-elect each of Mr. Tang Xun, Mr. Wong Yu Man, James, Prof. Hu Shanlian, Prof. Lu Chuanzhen, Dr. Lam Huen Sum and Mr. Liu Chenli as non-executive/independent non-executive Director (as the case may be).

LETTER FROM THE BOARD

Details of the Directors who are proposed to be re-elected at the AGM are set out in Appendix II to this circular.

(3) ANNUAL GENERAL MEETING

A notice convening the AGM of the Company to be held at 19/F., New Wing, 101 King's Road, Hong Kong on Friday, 10 August 2018 at 3:30 p.m. is set out in this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM in person, please complete and return the form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for holding of the AGM (i.e. no later than 3:30 p.m. on Wednesday, 8 August 2018 (Hong Kong time)) or any adjournment of such meeting. Completion and return of the form of proxy will not preclude you from attending and voting at the AGM or any adjourned meeting (as the case may be) should you so wish.

CLOSURE OF REGISTER OF MEMBERS

The AGM will be held on Friday, 10 August 2018. For determining the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, 7 August 2018 to Friday, 10 August 2018 (both dates inclusive) during which period no transfer of Shares will be effected. In order to qualify for attending and voting at the AGM, unregistered holders of the Shares should ensure that all share transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration not later than 4:30 p.m. on Monday, 6 August 2018.

GEM LISTING RULES REQUIREMENT FOR VOTING

Pursuant to Rule 17.47(4) of the GEM Listing Rules, vote of shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the AGM. An announcement on the poll vote results will be made by the Company after the AGM in the manner prescribed under Rule 17.47(5) of the GEM Listing Rules.

SHAREHOLDERS ABSTAIN FROM VOTING

None of the Shareholders is required to abstain from voting in respect of the resolutions to be proposed at the AGM.

LETTER FROM THE BOARD

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATIONS

The Directors consider that (i) the general mandates to the Directors for the issue and repurchase of Shares; and (ii) the re-election of the retiring Directors and continuous appointment of Prof. Hu Shanlian and Prof. Lu Chuanzhen as independent non-executive Directors are in interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend all Shareholders to vote in favour of the relevant resolutions to be proposed at the forthcoming AGM.

GENERAL

As at the Latest Practicable Date, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, none of the Directors, or the controlling Shareholder or their respective close associates had any interests in a business which competes or may compete with the business of the Group and have any other conflicts of interest with the Group.

Your attention is also drawn to the additional information set out in the Appendices to this circular.

This circular is in English and Chinese. In case of any inconsistency, the English version shall prevail.

By order of the Board
Hua Xia Healthcare Holdings Limited
Jiang Tao
Chief Executive Officer

This is an explanatory statement given to all Shareholders relating to the resolution to be proposed at the AGM authorising the Repurchase Mandate. It contains all the relevant information required pursuant to Rule 13.08 of the GEM Listing Rules which is set out as follows:

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 2,818,249,944 Shares of HK\$0.01 each.

Subject to the passing of the resolution in relation to the Repurchase Mandate and on the basis that no Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 2,818,249,944 Shares equivalent to approximately 10% of the total number of issued Shares. The repurchased Shares will be cancelled and the Company's issued share capital will be reduced accordingly by the number of Shares repurchased.

2. EXERCISE OF THE REPURCHASE MANDATE

Exercise in full of the Repurchase Mandate, on the basis of 2,818,249,944 Shares in issue as at the Latest Practicable Date, could result in up to 281,824,994 Shares listed on GEM or on another stock exchange recognised by the Securities and Futures Commission and the Stock Exchange under the Code on Share Buy-backs being repurchased by the Company during the period up to (i) the conclusion of the next annual general meeting of the Company after the AGM; (ii) the expiration of the period within which the next annual general meeting of the Company after the AGM is required by the Articles of Association or the Companies Law or any other applicable laws of the Cayman Islands to be held; or (iii) the revocation, variation or renewal of the repurchase mandate by ordinary resolution of the Shareholders in a general meeting, whichever occurs first.

3. REASONS FOR REPURCHASES

Although the Directors have no present intention to repurchase any Shares, they believe that the Repurchase Mandate will provide the Company the flexibility to make such repurchases when appropriate and is beneficial to the Company and the Shareholders. Such repurchases may, depending on market conditions and funding arrangements at the relevant time, lead to an enhancement of the net asset value of the Company and/or earning per Share.

4. FUNDING OF REPURCHASES

Repurchase of Shares will be funded out of funds legally available for such purpose in accordance with the memorandum of association, the Articles of Association and the applicable laws and regulations of the Cayman Islands.

The Company may not purchase its own securities on GEM for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

5. EFFECT OF EXERCISING THE REPURCHASE MANDATE

There might be a material adverse impact on the working capital or the gearing position of the Group as compared with the position disclosed in the audited financial statements for the year ended 31 March 2018, being the date to which the latest published audited financial statements of the Company were made up, in the event that the Repurchase Mandate is exercised in full. However, the Directors do not propose to exercise the Repurchase Mandate to such an extent as it would, in the circumstances, have a material adverse effect on the working capital requirements of the Group or on the gearing positions which in the opinion of the Directors are from time to time appropriate for the Group. The number of Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regard to the circumstances then prevailing.

6. SHARE PRICES

The highest and lowest closing prices at which Shares have been traded on GEM in each of the past twelve months preceding the Latest Practicable Date were as follows:

	Price per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2017		
July	0.146	0.128
August	0.165	0.128
September	0.147	0.122
October	0.216	0.123
November	0.180	0.141
December	0.145	0.130
2018		
January	0.147	0.125
February	0.130	0.112
March	0.138	0.118
April	0.125	0.117
May	0.125	0.119
June	0.126	0.117
July (up to the Latest Practicable Date)	0.118	0.116

7. UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that they will exercise the power of the Company to make repurchases pursuant to the proposed resolution in accordance with the GEM Listing Rules and the applicable laws of Hong Kong and in accordance with the regulations set out in the memorandum of association, the Articles of Association and also any applicable laws of the Cayman Islands.

None of the Directors nor, to the best of the knowledge and belief of the Directors having made all reasonable enquires, any of the close associates of any of the Directors has any present intention, in the event that the proposed Repurchase Mandate is approved by the Shareholders, to sell Shares to the Company.

As at the Latest Practicable Date, no core connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that he/she has a present intention to sell Shares to the Company nor has he/she undertaken not to sell any of the Shares held by him/her to the Company in the event that the Company is authorised to make repurchases of Shares.

8. THE HONG KONG CODE ON TAKEOVERS AND MERGERS

If as a result of a Share repurchase, a shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Takeovers Code. Accordingly, a shareholder or group of shareholders acting in concert, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, the register of the substantial shareholders maintained by the Company under section 336 of the SFO showed that the following parties had interests in the Shares representing 10% or more of the voting power at any general meeting of the Company:

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Solar Star Global Limited ("Solar Star") (Note 1)	1,581,959,460	Long	Beneficial owner	56.13%	62.37%
Ng Chi Lung (Note 1)	1,581,959,460	Long	Corporate interest	56.13%	62.37%
	59,000,000	Long	Personal interest	2.09%	2.33%
New Hope International (Hong Kong) Limited ("New Hope International") (Note 2)	343,217,539	Long	Beneficial owner	12.18%	13.53%
Southern Hope Enterprise Co., Ltd. [#] (南方希望實業有限公司) (Note 2)	343,217,539	Long	Corporate interest	12.18%	13.53%
New Hope Group Co., Ltd. [#] (新希望集團有限公司) (Note 2)	343,217,539	Long	Corporate interest	12.18%	13.53%

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Tibet Hengye Feng Industrial Co., Ltd. [#] (西藏恒業峰實業有限公司) (Note 2)	343,217,539	Long	Corporate interest	12.18%	13.53%
Mr. Liu Yonghao (Note 2)	343,217,539	Long	Corporate interest	12.18%	13.53%
Ms. Liu Chang (Note 2)	343,217,539	Long	Corporate interest	12.18%	13.53%
Ms. Li Wei (Note 2)	343,217,539	Long	Interest of spouse	12.18%	13.53%

Notes:

- Solar Star is interested in 1,581,959,460 Shares and 98,500,000 convertible preference shares of the Company. The issued share capital of Solar Star is owned as to 50% by Mr. Ng Chi Lung, 25% by Ms. Ng Si Wing and 25% by Ms. Ng Yin. Mr. Ng Chi Lung is deemed to be interested in the Shares and the convertible preference shares in which Solar Star is interested in under the SFO.
- New Hope International is interested in 343,217,539 Shares. The issued share capital of New Hope International is owned as to 75% by Southern Hope Enterprise Co., Ltd.[#] which is in turn owned as to 51% by New Hope Group Co., Ltd.[#] and as to 49% by Tibet Hengye Feng Industrial Co., Ltd.[#] Both New Hope Group Co., Ltd.[#] and Tibet Hengye Feng Industrial Co., Ltd.[#] are owned as to 62.34% by Mr. Liu Yonghao, as to 36.35% by Ms. Liu Chang and as to 1.31% by Ms. Li Wei. Mr. Liu Yonghao, Ms. Liu Chang and Ms. Li Wei are deemed to be interested in the Shares in which New Hope International is interested in under the SFO.

On the basis of the current shareholdings of above Shareholders, an exercise of the Repurchase Mandate in full will not result in them becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors have no intention to exercise the Repurchase Mandate to such an extent that will result in a requirement of the above Shareholders, or any other persons to make a general offer under the Takeovers Code. However, the Company may not repurchase Shares which would result in the number of Shares held by the public being reduced to less than 25%.

The GEM Listing Rules prohibit the Company from knowingly purchasing its securities on GEM from a “connected person”, that is, a director, chief executive or substantial shareholder of the Company or any of its subsidiaries or their respective close associates.

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, any of their close associates have any present intention to sell Shares to the Company or its subsidiaries under the Repurchase Mandate if such is approved by the Shareholders.

No core connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that it has a present intention to sell Shares to the Company or its subsidiaries, or has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

9. SHARE REPURCHASE MADE BY THE COMPANY

No Shares had been repurchased by the Company, whether on GEM or otherwise, in the last six months prior to the Latest Practicable Date.

Set out below are details of the Directors who are proposed to be re-elected at the AGM:

1. Mr. Tang Xun

Mr. Tang Xun (“Mr. Tang”), age 37, holds a Bachelor’s degree in Japanese from the Beijing International Studies University in 2004, and thereafter a Master’s degree in political economics from Graduate School of Peking University as an on-job postgraduate student in 2012. Mr. Tang Xun has over three years of experience in private equity investment, and is currently an executive director of Beijing Hosen Investment Management, LLP. Mr. Tang was appointed as a non-executive Director with effective from 10 March 2015.

Mr. Tang has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Mr. Tang is entitled to a monthly director’s fee of HK\$5,000 which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group’s remuneration policy and the prevailing market condition. He is also entitled to a discretionary bonus for each financial year, which is payable at the Board’s discretion and determined with reference to the Group’s results and performance for the financial year concerned.

Save as disclosed above, (i) Mr. Tang did not have, and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Mr. Tang does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Mr. Tang does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Mr. Tang that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Mr. Tang which needs to be brought to the attention of the Shareholders.

2. Dr. Wong Yu Man, James

Dr. Wong Yu Man, James (“Dr. Wong”), aged 65, holds two bachelor degrees in medicine and surgery from the University of Hong Kong. Dr. Wong also holds a doctorate degree in medicine from Freiburg University in Germany. He has over 30 years of experience in medical and healthcare services in Hong Kong. Dr. Wong was appointed as a non-executive Director on 20 March 2007.

Dr. Wong has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Dr. Wong is entitled to a monthly director’s fee of HK\$10,000 which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group’s remuneration policy and the prevailing market condition. He is also entitled to a discretionary bonus for each financial year, which is payable at the Board’s discretion and determined with reference to the Group’s results and performance for the financial year concerned.

Save as disclosed above, (i) Dr. Wong did not have and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Dr. Wong does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Dr. Wong does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Dr. Wong that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Dr. Wong which needs to be brought to the attention of the Shareholders.

3. Prof. Hu Shanlian

Prof. Hu Shanlian (“Prof. Hu”), aged 81, is a professor in Health Economics and has a Master degree in Science from the London School of Tropical Medicine and Hygiene. At present, he is the Director of Pharmacoeconomics Research and Evaluation Centre at the school of Public Health at Fudan University in the PRC. Prof. Hu is also the Senior Advisor of Shanghai Health Development Research Centre in the Shanghai Bureau of Health. Prof. Hu also held senior positions in the National Health Economic Institution and China Network of Training and Research in Health Economics and Financing between 1991 and 2005, which were supported by the Ministry of Health of the PRC and World Bank respectively. Prof. Hu was appointed as an independent non-executive Director on 30 July 2009.

Prof. Hu has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Prof. Hu is entitled to a monthly director’s fee of HK\$8,000 which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group’s remuneration policy and the prevailing market condition.

Save as disclosed above, (i) Prof. Hu did not have and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Prof. Hu does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Prof. Hu does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Prof. Hu that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Prof. Hu which needs to be brought to the attention of the Shareholders.

4. Prof. Lu Chuanzhen

Prof. Lu Chuanzhen (“Prof. Lu”), aged 80, is a neurologist and has over 50 years of medical professional experience. Prof. Lu is currently the lifetime professor of Shanghai Huashan Hospital in the PRC and a director in the World Health Organisation’s Neuroscience Research and Training Centre. Prof. Lu was formerly the chairman and director of the Institute of Neurology in Shanghai Medical University, the chairman of the Chinese Association of Neurology and chairman of the Shanghai association of Neurology in the Chinese Medical Society. Prof. Lu also has an international membership with New York Academy of Sciences. Prof. Lu was appointed as an independent non-executive Director on 30 July 2009.

Prof. Lu has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Prof. Lu is entitled to a monthly director’s fee of HK\$8,000 which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group’s remuneration policy and the prevailing market condition.

Save as disclosed above, (i) Prof. Lu did not have, and was not deemed to have, any interests or short positions in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Prof. Lu does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Prof. Lu does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Prof. Lu that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Prof. Lu which needs to be brought to the attention of the Shareholders.

5. Dr. Lam Huen Sum

Dr. Lam Huen Sum (“Dr. Lam”), aged 38, was graduated from Hong Kong Baptist University with a bachelor’s degree in arts, diploma in education, master degree in social sciences and master of philosophy and the University of Hong Kong with a doctor of philosophy. Dr. Lam was appointed as an independent non-executive Director on 9 July 2018.

Dr. Lam has been an adjunct professor at 山東濟南大學 (University of Jinan*), a member of the Advisory Board of 澳門城市大學公開學院 (Open Institute, City University of Macau*), a specialist in 香港學術及職業資歷評審局 (Hong Kong Council for Accreditation of Academic and Vocational Qualifications), a member of 戴麟趾爵士康樂基金委員會 (Sir David Trench Fund Committee of HKSAR), a Fellow and Executive Board Member/Accreditor of Medical and Health Board of International Industry and Professional Accreditation Association. Dr. Lam has been appointed by Hong Kong College of Technology, as an external examiner and a consultant since September 2016 and January 2017 respectively. Dr. Lam is an independent non-executive director of Sunway International Holdings Limited (stock code: 58), a company listed on the Main Board of the Stock Exchange, since 12 June 2017.

On 9 July 2018, the Company entered into a letter of appointment with Dr. Lam, pursuant to which Dr. Lam shall hold office until the next annual general meeting of the Company and thereafter shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the articles of association of the Company. Dr. Lam is entitled to a director’s fee of HK\$10,000 per month which is determined by arm’s length negotiation between Dr. Lam and the Company and with reference to his duties and responsibilities. The amount of the remuneration has been approved by the Board and the remuneration committee of the Company.

Save as disclosed above, (i) Dr. Lam did not have and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Dr. Lam does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Dr. Lam does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Dr. Lam that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Dr. Lam which needs to be brought to the attention of the Shareholders.

6. Mr. Liu Chenli

Mr. Liu Chenli (“Mr. Liu”), aged 37, graduated from the University of Hong Kong with a degree of doctor of philosophy in 2011. Mr. Liu is a Professor of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences and specialized in Synthetic Biology Engineering Research. Mr. Liu was an independent non-executive director of Sunway International Holdings Limited (stock code: 58), a company listed on the Main Board of the Stock Exchange, for the period from 29 May 2015 to 9 May 2017 and was re-designated as a non-executive director with effect from 10 May 2017. Dr. Lam was appointed as an independent non-executive Director on 9 July 2018.

On 9 July 2018, the Company entered into a letter of appointment with Mr. Liu, pursuant to which Mr. Liu shall hold office until the next annual general meeting of the Company and thereafter shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the articles of association of the Company. Mr. Liu is entitled to a director’s fee of HK\$10,000 per month which is determined by arm’s length negotiation between Mr. Liu and the Company and with reference to his duties and responsibilities. The amount of the remuneration has been approved by the Board and the remuneration committee of the Company.

Save as disclosed above, (i) Mr. Liu did not have, and was not deemed to have, any interests or short positions in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Mr. Liu does not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Mr. Liu does not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, there is no further information relating to Mr. Liu that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there is no other matter in relation to the re-election of Mr. Liu which needs to be brought to the attention of the Shareholders.

NOTICE OF ANNUAL GENERAL MEETING



HUA XIA HEALTHCARE HOLDINGS LIMITED

華夏醫療集團有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

NOTICE IS HEREBY GIVEN THAT the annual general meeting (“AGM”) of the shareholders (“Shareholders”) of Hua Xia Healthcare Holdings Limited (the “Company”) will be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Friday, 10 August 2018 at 3:30 p.m. for the following purposes:

1. to receive and consider the audited financial statements and the reports of the directors and auditors of the Company and its subsidiaries for the year ended 31 March 2018;
2. to re-elect the retiring directors of the Company (“Directors”), namely Mr. Tang Xun, Dr. Wong Yu Man, James, Prof. Hu Shanlian, Prof. Lu Chuanzhen, Dr. Lam Huen Sum and Mr. Liu Chenli;
3. to authorise the board of Directors (the “Board”) to fix the remunerations of the Directors;
4. to re-appoint HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration; and

As special business, to consider and, if thought fit, pass with or without amendments the following proposed resolutions numbered 5 to 7 as ordinary resolutions:

ORDINARY RESOLUTIONS

5. **THAT:**
 - (a) subject to paragraph (c) of this resolution, and pursuant to the Rules Governing the Listing of Securities on GEM (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company and to allot, issue and deal with additional shares (“Shares”) in the capital of the Company and to make or grant offers, agreements and options (including bonds, notes, warrants, debentures and securities convertible into Shares) which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;

* For identification purpose only

NOTICE OF ANNUAL GENERAL MEETING

- (b) the approval in paragraph (a) of this resolution shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;

- (c) the total number of Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as defined below); or (ii) the grant or exercise of any option under the any share option scheme of the Company or any other option scheme or similar arrangement of the Company for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries of Shares or rights to acquire Shares; or (iii) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company in force from time to time; or (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any existing warrants of the Company or any existing securities of the Company which carry rights to subscribe for are convertible into Shares, shall not exceed the aggregate of:
 - (i) 20% of the total number of issued Shares on the date of the passing of this resolution; and

 - (ii) (if the Directors are so authorised by a separate ordinary resolution of the shareholders of the Company) the number of Shares repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10% of the total number of issued Shares on the date of the passing of this resolution).

and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

NOTICE OF ANNUAL GENERAL MEETING

- (d) for the purpose of this resolution:
- (aa) “**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:
- (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the memorandum of association and articles of association of the Company, or any other applicable laws of the Cayman Islands to be held; and
 - (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Directors by this resolution.
- (bb) “**Rights Issue**” means an offer of shares in the Company, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of shares in the Company on the register on a fixed record date in proportion to their holdings of Shares (subject to such exclusion and arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expenses or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognized regulatory body or any stock exchange applicable to the Company).

NOTICE OF ANNUAL GENERAL MEETING

6. **THAT:**

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as defined in resolution 5(d)(aa) set out in the notice) of all powers of the Company to purchase its shares on the GEM or any other stock exchange on which the shares of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the SFC, the Stock Exchange or any other stock exchange as amended from time to time and all applicable laws in this regard, be and the same is hereby generally and unconditionally approved; and
- (b) the total number of Shares which may be purchased by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10% of the total number of issued Shares as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly.

7. **THAT** conditional upon resolutions numbered 5 and 6 of this notice being passed, the general mandate granted to the Directors to allot, issue and deal with additional Shares pursuant to resolution numbered 5 be and is hereby extended by the addition thereto the number of Shares repurchased by the Company under the authority granted to the Directors pursuant to resolution numbered 6.

By order of the Board
Hua Xia Healthcare Holdings Limited
Jiang Tao
Chief Executive Officer

Hong Kong, 11 July 2018

Registered office:

P.O. Box 10008
Willow House
Cricket Square
Grand Cayman KY1-1001
Cayman Islands

Head office and principal place of

business in Hong Kong:
19th Floor, New Wing
101 King's Road
Hong Kong

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. A member entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and, subject to the provisions of the articles of association of the Company, to vote on his/her/its behalf. A proxy needs not be a member of the Company but must be present in person at the AGM to represent the member. If more than one proxy is so appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.
2. A form of proxy for use at the AGM is enclosed with the circular of the Company dated 11 July 2018. Whether or not you intend to attend the AGM in person, you are encouraged to complete and return the enclosed form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the AGM or any adjournment thereof, should he/she/its so wish.
3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, not less than 48 hours before the time appointed for holding the AGM (i.e. no later than 3:30 p.m. on Wednesday, 8 August 2018 (Hong Kong time)) or any adjournment thereof.
4. In the case of joint holders of Shares, any one of such holders may vote at the AGM, either personally or by proxy, in respect of such Shares as if he/she/its was solely entitled thereto, but if more than one such joint holders are present at the AGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such Shares shall alone be entitled to vote in respect thereof.
5. Any voting at the meeting shall be taken by poll.
6. In the case of any inconsistency between the Chinese translation and the English text hereof, the English text shall prevail.